The Latest Insights into Suspension and Debarment Activities Across the Federal Government
Client Alert | 1 min read | 02.05.21
The annual Interagency Suspension and Debarment Committee (ISDC) recently issued its annual report to Congress. The report, found here, contains details describing improvements to the federal suspension and debarment process and a summary of each agency’s suspension and debarment activities in Fiscal Year 2019. Throughout FY2019, the ISDC pursued a strengthened understanding and awareness of suspension and debarment activities across the federal acquisition and financial assistance communities, and continued to focus on modernizing/streamlining lead agency coordination. Otherwise, while the total numbers of referrals and suspensions increased in FY2019 compared to FY2018, proposed debarments and debarments continued to decline. In addition, the ISDC notes that from FY2018 to FY2019 agencies better utilized pre-notice letters to notify individuals or entities that the Suspension and Debarment Official (SDO) was considering SDO action, allowing the recipient an opportunity to respond before formal SDO action.
Contacts
Insights
Client Alert | 4 min read | 01.07.26
On December 17, 2025, the U.S. Food and Drug Administration (FDA) issued a request for information (RFI) on a proposal designed to help the FDA engage more directly with innovative, venture-backed companies focused on biotechnology, medical devices, AI, and regulatory technology.[i]The RFI includes 19 questions, with responses due by 2:00 p.m. ET on January 18, 2026.
Client Alert | 3 min read | 01.07.26
CMMC for AI? Defense Policy Law Imposes AI Security Framework and Requirements on Contractors
Client Alert | 3 min read | 01.07.26
New Year, Same CIPA Uncertainty – When Will the Appellate Courts Enter the Chat?
Client Alert | 11 min read | 01.07.26
